Autoimmune Liver Disease in Northern Virginia

← Patient Education

Autoimmune liver disease is a group of conditions in which the body's immune system, which normally fights infection, mistakenly attacks the liver or the bile ducts that drain it. The three main types are autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Many people in Arlington, Annandale, and across Northern Virginia first hear these names after a routine blood test shows elevated liver enzymes, sometimes years before they notice any symptoms. This guide explains what each type of autoimmune liver disease is, who tends to get it, how it is diagnosed, how it is treated or monitored, and what living with it usually involves.

This article is general education, not medical advice. The three conditions behave very differently, and what applies to you depends on your test results, your history, and your physicians' assessment.

What autoimmune liver disease means

In an autoimmune disease, the immune system makes antibodies and immune cells that target the body's own tissue. When that target is the liver, the result is ongoing inflammation. Over years, inflammation can lead to scarring, and heavy scarring is called cirrhosis.

The type of autoimmune liver disease depends on which part of the liver is under attack:

• Autoimmune hepatitis targets the liver cells themselves.
• Primary biliary cholangitis targets the small bile ducts inside the liver.
• Primary sclerosing cholangitis scars the bile ducts both inside and outside the liver.

Bile is the digestive fluid the liver makes, and the bile ducts are the tubes that carry it to the intestine. When bile ducts are damaged, bile backs up into the liver and injures it. That is why PBC and PSC are often grouped together as cholestatic diseases, meaning diseases of slowed bile flow.

The main source for this guide is the American Association for the Study of Liver Diseases (AASLD), the U.S. society for liver specialists, which publishes separate practice guidance for each condition: autoimmune hepatitis (2019), PBC (2018, with a 2021 update), and PSC (2022). We also draw on the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Autoimmune hepatitis

The AASLD describes autoimmune hepatitis as an immune-mediated inflammatory liver disease of uncertain cause that affects all ages, both sexes, and all ethnic groups. Without treatment, the NIDDK notes, it can get worse and lead to cirrhosis and liver failure. With treatment, the AASLD's patient summary notes, that damage can be prevented in most cases.

Who gets autoimmune hepatitis

The condition is more common in women. The AASLD guidance and the NIDDK both report that 71 to 95 percent of adults with autoimmune hepatitis are women. The NIDDK puts the rate at roughly 4 to 43 per 100,000 adults, depending on the population studied. It can start at any age, including in childhood and after age 60.

Medications can sometimes trigger a liver injury that looks like autoimmune hepatitis. The AASLD notes that a drug reaction has been implicated in 2 to 17 percent of people with classic features of the disease, and it names the antibiotics minocycline and nitrofurantoin and the IBD medicine infliximab as the most common. This is one reason your physician will ask about every medication and supplement you have taken, including those you stopped months ago.

Symptoms of autoimmune hepatitis

According to the AASLD guidance, 25 to 34 percent of people with autoimmune hepatitis have no symptoms when it is found, usually through abnormal liver tests. Most others develop vague, long-running symptoms:

• Fatigue, which the AASLD describes as the main complaint in 85 percent of patients
• A general feeling of being unwell
• Joint aches
• Missed menstrual periods
• Yellowing of the skin or eyes (jaundice) in some people

Less often, the disease starts suddenly and looks like an acute hepatitis. Very rarely, the NIDDK notes, it causes acute liver failure. One detail clinicians watch for: the AASLD notes that itching is not typical of autoimmune hepatitis, which helps separate it from the bile duct diseases below.

How autoimmune hepatitis is diagnosed

There is no single test for autoimmune hepatitis. The AASLD describes a combination:

• Elevated liver enzymes, especially ALT and AST
• A high IgG level (a type of antibody protein) and/or autoantibodies, most often antinuclear antibody (ANA) and smooth muscle antibody (SMA)
• Ruling out look-alikes, including hepatitis B and C, inherited conditions, bile duct disease, and drug-induced injury
• A liver biopsy showing a typical pattern of inflammation

The AASLD patient summary is direct on the last point: autoimmune hepatitis should not be diagnosed without a liver biopsy. It also notes that about one in five people with the disease have no autoantibodies in their blood, so a negative antibody test does not rule it out. The AASLD reports that 28 to 33 percent of adults already have cirrhosis when they are diagnosed, which is one reason unexplained elevated liver enzymes deserve a full evaluation.

How autoimmune hepatitis is treated

Autoimmune hepatitis is treated by calming the immune system. For adults and children without cirrhosis or a severe acute presentation, the AASLD suggests starting with a steroid, either budesonide or prednisone, together with azathioprine. Budesonide tends to cause fewer steroid side effects, such as weight gain and bone thinning, but the AASLD advises that it not be used in people with cirrhosis or severe acute disease. If first-line treatment does not work well enough or is not tolerated, the AASLD suggests mycophenolate mofetil or tacrolimus as second-line options.

The goal is remission, defined as normal liver enzymes and a normal IgG level. Some points from the guidance that patients often ask about:

• Treatment is long term. Stopping medication is considered only after liver enzymes and IgG have been normal for at least two years.
• Stopping works for a minority. The AASLD patient summary notes that up to 80 percent of people relapse after medication is stopped, often within the first year, so blood tests continue for life.
• Pregnancy needs planning. The AASLD advises being in remission for a year before conception and continuing steroid or azathioprine maintenance during pregnancy. Mycophenolate must not be used in pregnancy.

Please do not stop or change an immune-suppressing medicine on your own. A flare can be serious, and dose changes are managed with your physician.

Primary biliary cholangitis (PBC)

In primary biliary cholangitis, the immune system slowly destroys the small bile ducts inside the liver. As the ducts are lost, bile builds up and damages the liver, which over many years can lead to cirrhosis. The NIDDK notes that the disease used to be called primary biliary cirrhosis.

Who gets PBC

PBC affects women far more often than men. The NIDDK reports that in 2014, about 58 of every 100,000 U.S. women and about 15 of every 100,000 U.S. men had PBC, and that the average age at diagnosis is 60. Family history matters: the AASLD notes that the PBC antibody is found in about 13 percent of parents, siblings, and children of people with PBC, compared with about 1 percent of the general population, and is most common in sisters.

Symptoms of PBC

Many people are now diagnosed before any symptoms appear, after a routine blood test shows a high alkaline phosphatase. When symptoms do occur, the AASLD lists two main ones:

• Fatigue, reported by 50 to 78 percent of patients and the most common symptom
• Itching, which can be anywhere on the body, is often worse in the evening, and can flare with heat or contact with clothing

PBC often travels with other autoimmune conditions. The AASLD names Sjögren syndrome (dry eyes and dry mouth), scleroderma, and Raynaud disease, and notes a possible link with thyroid disease. The NIDDK adds that PBC can lead to high cholesterol, bone thinning, and low levels of vitamins A, D, E, and K.

How PBC is diagnosed

The AASLD states that PBC can be diagnosed when two of these three are present:

• An elevated alkaline phosphatase, a sign of slowed bile flow
• A positive antimitochondrial antibody (AMA), or another PBC-specific antibody if the AMA is negative
• A liver biopsy showing the typical bile duct damage

Because most people meet the first two, the AASLD patient summary notes that a liver biopsy is rarely needed. A biopsy may be considered when the picture is unclear, or when ALT is high enough to raise the question of autoimmune hepatitis at the same time. When alkaline phosphatase is high, the American College of Gastroenterology recommends an ultrasound to check that the bile ducts are not blocked by something else, such as gallstones.

How PBC is treated

The first-line treatment is ursodeoxycholic acid, also called ursodiol or UDCA, a bile acid taken by mouth. The AASLD recommends it for people with PBC and abnormal liver tests at any stage. In an international analysis of 4,845 patients cited in the guidance, people treated with ursodiol had markedly better transplant-free survival at 5, 10, and 15 years than untreated patients.

The response is checked after about 12 months. When liver tests have not improved enough, a second medicine may be added. The options here have changed since the 2018 guidance: according to their U.S. labels, the Food and Drug Administration approved two newer medicines, elafibranor and seladelpar, in 2024 for adults with PBC who have not responded well enough to ursodiol or cannot tolerate it. Both were approved under the FDA's accelerated pathway, based on lowering alkaline phosphatase, and their labels note that benefits on survival or liver complications have not yet been shown. A liver specialist can explain which options currently apply to your situation.

Symptoms are treated separately, because ursodiol does not reliably relieve them. The AASLD describes medicines that bind bile acids in the gut as the first step for itching, with other options if itching persists. It also notes that fatigue in PBC can have other contributors worth checking, such as an underactive thyroid, depression, anemia, and sleep apnea.

Primary sclerosing cholangitis (PSC)

In primary sclerosing cholangitis, the bile ducts inside and outside the liver become inflamed and scarred, and over time narrow or close. The NIDDK estimates that about 5 to 16 of every 100,000 people have PSC. Unlike autoimmune hepatitis and PBC, it is more common in men: the NIDDK notes it affects twice as many males as females and is most often diagnosed between ages 30 and 40, though it can occur at any age.

PSC and inflammatory bowel disease

The strongest link in autoimmune liver disease is between PSC and inflammatory bowel disease. The NIDDK reports that about 7 in 10 people with PSC also have IBD, most commonly ulcerative colitis. The AASLD notes that colitis in people with PSC is often mild or quiet, and that IBD can appear after PSC is diagnosed. For that reason, the AASLD advises that anyone diagnosed with PSC who does not already have known IBD have a colonoscopy with biopsies at diagnosis, repeated about every five years if no colitis is found.

The link runs the other way too. If you have ulcerative colitis and a routine blood test shows a rising alkaline phosphatase, your gastroenterologist may look for PSC.

Symptoms of PSC

The AASLD notes that nearly half of adults with PSC have symptoms when they are diagnosed, and another 22 percent develop them within five years. Symptoms include fatigue, pain in the upper abdomen, itching, and fever. Episodes of fever, chills, and jaundice can signal a bile duct infection, called cholangitis, which needs prompt care.

How PSC is diagnosed

PSC is usually diagnosed with an MRI of the bile ducts, called MRCP (magnetic resonance cholangiopancreatography), which can show the typical pattern of narrowed and widened ducts. The AASLD advises that ERCP, an endoscopic procedure that can reach the bile ducts, should be avoided for diagnosing PSC because of its risks, and reserved for treating problem narrowings or sampling them when cancer is a concern. When the MRCP is normal but PSC is still suspected, a liver biopsy can identify a form called small-duct PSC.

How PSC is managed and monitored

The AASLD guidance states plainly that there is currently no effective medical therapy for PSC. It notes that ursodiol can be considered, and continued if liver tests or symptoms improve meaningfully after 12 months, and it encourages people with PSC to consider clinical trials. Care focuses on treating complications and watching for cancer, because PSC raises the risk of several:

• Bile duct cancer. The NIDDK estimates a 10 to 20 percent lifetime chance. The AASLD advises yearly imaging, preferably MRI/MRCP, sometimes with a blood test called CA 19-9, for adults with PSC of the larger ducts.
• Gallbladder cancer. The yearly imaging also looks at the gallbladder, and the AASLD advises considering gallbladder removal for polyps larger than 8 millimeters.
• Colon cancer in people with both PSC and IBD. The AASLD advises surveillance colonoscopy with biopsies every one to two years.
• Liver cancer in people with PSC and cirrhosis.

The outlook varies widely. The AASLD notes that older referral-center studies reported a median time to death or liver transplant as short as 9 years, while more recent population-based studies estimate 21 years or longer. For people whose PSC progresses to liver failure, liver transplant is an option, although the AASLD notes the disease returns in 20 to 30 percent of transplanted livers.

Autoimmune liver disease compared

Because the names sound alike, it helps to see the three side by side.

• What is attacked: autoimmune hepatitis targets liver cells; PBC targets small bile ducts inside the liver; PSC scars larger and smaller bile ducts inside and outside the liver.
• Who it affects most: autoimmune hepatitis and PBC mainly affect women; PSC is twice as common in men and strongly tied to ulcerative colitis.
• The telltale lab pattern: autoimmune hepatitis raises ALT and AST along with IgG; PBC and PSC mainly raise alkaline phosphatase.
• Key test: liver biopsy for autoimmune hepatitis; the AMA antibody for PBC; MRCP for PSC.
• Main treatment: steroids and azathioprine for autoimmune hepatitis; ursodiol, with add-on medicines if needed, for PBC; no proven medicine for PSC, so monitoring and complication care lead.

When autoimmune liver disease overlaps

Some people have features of more than one condition, such as autoimmune hepatitis with PBC or with PSC. The AASLD and NIDDK both describe these overlaps. They matter because treatment may need to address both parts, and a liver biopsy is often what sorts them out.

Other autoimmune conditions alongside autoimmune liver disease

Autoimmune conditions tend to cluster. The AASLD reports that 14 to 44 percent of people with autoimmune hepatitis have another autoimmune disease, with autoimmune thyroid disease the most common. The NIDDK also lists celiac disease, rheumatoid arthritis, type 1 diabetes, ulcerative colitis, vitiligo, and lupus. The AASLD advises screening for celiac disease and thyroid disease when autoimmune hepatitis is diagnosed. If you already live with one of these conditions and your liver tests come back abnormal, tell the physician reviewing them.

Living with autoimmune liver disease

All three are long-term conditions followed by a gastroenterologist or hepatologist over years. Beyond the liver itself, the guidance documents point to several areas of ongoing care:

• Bone health. Long steroid courses in autoimmune hepatitis and the bile flow problems in PBC both raise the risk of bone thinning. The AASLD guidance for each condition describes bone density testing and vitamin D checks.
• Vaccines. The AASLD advises vaccinating people with autoimmune hepatitis according to CDC guidelines, especially against hepatitis A and B.
• Cirrhosis care. When cirrhosis is present, care includes checking for enlarged veins in the esophagus with an upper endoscopy and liver cancer surveillance imaging, typically every six months.
• Mental health. The AASLD notes that depression and anxiety are more common in people with autoimmune hepatitis, often driven by worry about the disease, and lists anxiety and depression among the symptoms of PSC. Raising this with your physicians is part of good care.
• Alcohol and medications. Ask your physician before starting new medicines or supplements, and about alcohol, since both can add stress to an already inflamed liver.

Autoimmune liver disease is one of several conditions that can stay quiet for years. Our guide to silent digestive conditions explains why abnormal bloodwork is so often the first clue.

Autoimmune liver disease symptoms that need prompt attention

Most autoimmune liver disease is managed through scheduled visits. Some symptoms call for same-day care or an emergency department: yellowing of the skin or eyes that is new or worsening, fever with chills and pain in the upper right abdomen, vomiting blood or passing black stools, a rapidly swelling abdomen, or new confusion or unusual drowsiness. If you are on treatment for autoimmune hepatitis and develop dark urine or jaundice, contact your physician promptly rather than waiting for your next appointment. Our guide to when to see a gastroenterologist explains how to tell a scheduled concern from an urgent one.

The full AASLD guidance documents for autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis are available for those who want the clinical detail, and the NIDDK has plain-language pages on autoimmune hepatitis, PBC, and PSC.

Autoimmune liver disease care in Northern Virginia with GC of NoVA

Gastroenterology Center of Northern Virginia sees patients across Arlington, Annandale, and the surrounding communities who have been referred for abnormal liver tests or a suspected autoimmune liver disease. Our physicians can review your results and how they have changed over time, order the blood work and imaging that fit your pattern, coordinate further testing when it is needed, and work with your other physicians on long-term follow-up. For people with ulcerative colitis or Crohn's disease, that includes keeping an eye on the liver tests that can point to PSC. We see patients at our Arlington office, next to VHC Health, and our Annandale office, in the Woodburn Medical complex.

If you are coming for an evaluation of your liver, our guide to elevated liver enzymes explains how abnormal results are sorted out, and our guide to your first gastroenterologist visit covers what to bring. For a liver visit, that includes copies of past bloodwork, any imaging reports, and a complete list of medications and supplements, including ones you have stopped in the past year. To schedule, contact our Arlington office at (703) 522-7476 or our Annandale office at (703) 560-6106, or learn more at gcofnova.com.

This article is for general education and is not medical advice. Talk with a qualified gastroenterologist about your symptoms, diagnosis, and treatment options.